These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26706241)

  • 1. Microtubule-stabilizing agents: New drug discovery and cancer therapy.
    Zhao Y; Mu X; Du G
    Pharmacol Ther; 2016 Jun; 162():134-43. PubMed ID: 26706241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in microtubule-stabilizing agents.
    Cao YN; Zheng LL; Wang D; Liang XX; Gao F; Zhou XL
    Eur J Med Chem; 2018 Jan; 143():806-828. PubMed ID: 29223097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microtubule stabilising agents for cancer chemotherapy.
    Zhao Y; Fang WS; Pors K
    Expert Opin Ther Pat; 2009 May; 19(5):607-22. PubMed ID: 19441937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The binding sites of microtubule-stabilizing agents.
    Field JJ; Díaz JF; Miller JH
    Chem Biol; 2013 Mar; 20(3):301-15. PubMed ID: 23521789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of microtubule stabilization by laulimalide and peloruside A.
    Prota AE; Bargsten K; Northcote PT; Marsh M; Altmann KH; Miller JH; Díaz JF; Steinmetz MO
    Angew Chem Int Ed Engl; 2014 Feb; 53(6):1621-5. PubMed ID: 24470331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization.
    Feyen F; Cachoux F; Gertsch J; Wartmann M; Altmann KH
    Acc Chem Res; 2008 Jan; 41(1):21-31. PubMed ID: 18159935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanism of action of microtubule-stabilizing anticancer agents.
    Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO
    Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
    Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH
    Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
    Broggini-Tenzer A; Sharma A; Nytko KJ; Bender S; Vuong V; Orlowski K; Hug D; O'Reilly T; Pruschy M
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25694444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epothilones: how pharmacology relates to clinical utility.
    Michaud LB
    Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells.
    Wilmes A; O'Sullivan D; Chan A; Chandrahasen C; Paterson I; Northcote PT; La Flamme AC; Miller JH
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):117-26. PubMed ID: 20848285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines.
    Gaitanos TN; Buey RM; Díaz JF; Northcote PT; Teesdale-Spittle P; Andreu JM; Miller JH
    Cancer Res; 2004 Aug; 64(15):5063-7. PubMed ID: 15289305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents.
    Mooberry SL; Tien G; Hernandez AH; Plubrukarn A; Davidson BS
    Cancer Res; 1999 Feb; 59(3):653-60. PubMed ID: 9973214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent.
    Liu J; Towle MJ; Cheng H; Saxton P; Reardon C; Wu J; Murphy EA; Kuznetsov G; Johannes CW; Tremblay MR; Zhao H; Pesant M; Fang FG; Vermeulen MW; Gallagher BM; Littlefield BA
    Anticancer Res; 2007; 27(3B):1509-18. PubMed ID: 17595769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination.
    Bergstralh DT; Ting JP
    Cancer Treat Rev; 2006 May; 32(3):166-79. PubMed ID: 16527420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microtubule-stabilizing agents: a growing class of important anticancer drugs.
    Altmann KH
    Curr Opin Chem Biol; 2001 Aug; 5(4):424-31. PubMed ID: 11470606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?
    Fanale D; Bronte G; Passiglia F; Calò V; Castiglia M; Di Piazza F; Barraco N; Cangemi A; Catarella MT; Insalaco L; Listì A; Maragliano R; Massihnia D; Perez A; Toia F; Cicero G; Bazan V
    Anal Cell Pathol (Amst); 2015; 2015():690916. PubMed ID: 26484003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peloruside A: a lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune disease.
    Kanakkanthara A; Northcote PT; Miller JH
    Nat Prod Rep; 2016 Apr; 33(4):549-61. PubMed ID: 26867978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods for studying microtubule binding site interactions: zampanolide as a covalent binding agent.
    Field JJ; Calvo E; Northcote PT; Miller JH; Altmann KH; Díaz JF
    Methods Cell Biol; 2013; 115():303-25. PubMed ID: 23973080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.